IVIVA Medical, Inc. develops bio-artificial platforms and systems to provide therapies. It develops alternative end-state renal disease therapies that alleviate donor organ demand for patients; disease and pathology modeling; and bioreactor systems. The company was incorporated in 2013 and is based in Beverly, Massachusetts.
Viscient Biosciences is a biotechnology company working at the intersection of human 3D tissue technology and multi-omics (genomics, transcriptomics, metabolomics) analysis to develop drugs across a range of therapeutic areas, with an initial focus in non-alcoholic steatohepatitis (NASH,“fatty liver disease”).
Founded and staffed by a team composed of former Organovo and Ardea Biosciences scientists and entrepreneurs, Viscient is driving a revolution in drug discovery, overthrowing the old paradigm of discovery in animal models.
Repair Biotechnologies is a developer of clinical gene and protein therapies intended to focus on the reversal of age-associated thymic atrophy and consequent loss of immune function. The company's platform is committed to developing treatments for ageing and age-related diseases that address the root causes of these conditions, enabling human beings to improve their health span through targeting the causes of age-related diseases and ageing itself.
X-Vax Technology is a biotechnology company focused on the preclinical and clinical development of vaccines against pathogens that cause mucosal infections such as herpes, influenza, tuberculosis and HIV, affecting hundreds of millions of people around the globe. They believe that inducing antibodies that mediate the killing of infected cells will provoke an entirely new and effective immune response – so that they can finally beat these pathogens. The company was founded in 2015 and based in Jupiter, Florida.
Repair Biotechnologies is a developer of clinical gene and protein therapies intended to focus on the reversal of age-associated thymic atrophy and consequent loss of immune function. The company's platform is committed to developing treatments for ageing and age-related diseases that address the root causes of these conditions, enabling human beings to improve their health span through targeting the causes of age-related diseases and ageing itself.
Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer. It offers potent vaccines and immunotherapies that enables precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body's own system of immune defenses.
KitoTech Medical, Inc. develops microMend, which is a medical product for closing wounds, including lacerations and surgical incisions. KitoTech Medical, Inc. was formerly known as Marco Pharmaceuticals, Inc. The company was founded in 2011 and is based in Seattle, Washington.
Our mission is to provide effective and patient centric treatment for hypertension- including resistant hypertension. In doing so creating a universal platform for the effective treatment of hypertension as well as for the distribution of fixed dose combination [FDC] hypertensive drugs such as Prestalia® and those in our pipeline. The company commercial product Prestalia® is approved by US FDA for the treatment of hypertension and being commercialized through the DyrctAxess platform. The company is also developing and commercializing late stage, non-addictive pain therapeutics. The company’s ‘next-generation of celecoxib,’ including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combatting the opioid epidemic.
Elevian, Inc., a biotech company, develops medicines to restore regenerative capacity to prevent and treat age-related diseases. It develops therapeutics that regulate Growth Differentiation Factor 11 (GDF11) protein and other circulating factors to restore natural regenerative capacity. The company also focuses on treating stroke recovery, Alzheimer’s disease, coronary artery disease, and Type 2 diabetes. Elevian, Inc. was founded in 2017 and is based in Menlo Park, California.
Theragene Pharmaceuticals combines innovative science and efficiency to develop life-saving therapies for many debilitating diseases. As a biopharmaceutical company operating in both the US and Asia, it delivers unique product development models, utilizing the strengths of each region, while delivering safe, effective treatments. Its mission is to provide cutting-edge science, through resourceful product models, that significantly advance each product from the preclinical stage to finished product. From advancements in oncology to novel drug formulations, they are developing tomorrow's medicine.
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the CXCR4 chemokine receptor, currently undergoing various clinical trials. Mavorixafor is in Phase III trials for treating patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and is also being tested in Phase Ib trials for severe congenital neutropenia and Waldenström macroglobulinemia, alongside a Phase IIa trial for clear cell renal cell carcinoma. Additionally, X4 Pharmaceuticals is advancing X4P-002, aimed at treating glioblastoma multiforme, and is developing X4P-003 for primary immune deficiencies. The company has established a license agreement with Abbisko Therapeutics to explore the use of mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.
Klotho Therapeutics, Inc. is a biotechnology company that develops Klotho protein that works on reducing the process of aging and slows the progression of kidney diseases. The company’s Klotho protein prevents chronic kidney diseases, acute kidney injuries, diabetes, and cancer. The company was incorporated in 2016 and is based in San Diego, California.
Fisker, Inc. is a designer and manufacturer of electric vehicles, focusing on eco-friendly and innovative mobility solutions. Headquartered in Manhattan Beach, California, the company aims to create vehicles that evoke strong emotional responses while promoting sustainability. Fisker gained early recognition for the Fisker Karma, one of the first luxury plug-in hybrid electric vehicles, which debuted at the 2008 North American International Auto Show and began deliveries in 2011. However, production of the Karma was halted in November 2012 due to the bankruptcy of its battery supplier. The design and production assets for the Karma were later acquired by a Chinese conglomerate in 2014. Today, Fisker continues to develop electric vehicles, emphasizing both performance and environmental responsibility.
Curtana Pharmaceuticals, Inc. develops novel molecule and targeted therapies for the treatment of brain cancer. The company advances CT-179, a novel small molecule therapy to prolong survival in relevant animal models. Curtana Pharmaceuticals, Inc. was founded in 2013 and is based in Austin, Texas.
WinSanTor Inc. is a clinical-stage biotechnology company based in San Diego, California, established in 2011. The company specializes in the discovery and development of treatments for various forms of peripheral neuropathies, such as diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, and HIV-induced neuropathy. WinSanTor is engaged in identifying and developing therapeutic compounds, including WST57, aimed at providing neuroprotection and promoting neuroregeneration in degenerating neurons.
Lubris BioPharma, LLC, a biopharmaceutical company, produces and commercializes lubricin, a recombinant version of the human protein. It offers its product for the treatment of dry eye, osteoarthritis, and other age and inflammation-related conditions. The company was founded in 2009 and is based in Framingham, Massachusetts.